entertainment -WSS

entertainment

author：focus 2025-08-11 08:00:47 - browse：55

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Large hospital system sues Multiplan for low

Wikipedia

WSS

Target recalls 2.2 million additional candles due to laceration, burn hazards

Covid’s new normal has set in amid another rise in cases

After John Oliver segment, STAT readers share their opioid

Maui funeral service workers on devastation of fires: 'I'm in shock'

The struggle to figure out which patients 'deserve' Wegovy

White House drug shortages task force keeps mum with Congress

explore

entertainment

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

CDC overhauls leadership of center that led response to Covid

Hollywood unions extend contract negotiations for actors

White House drug shortages task force keeps mum with Congress

Drug repurposing or repositioning? The language matters

PBMs drew scrutiny in House hearing — and so did pharma

Hepatitis C has a cure — but many Americans still lack access to it

Medicare to pay more for cardiac rehab in hospital outpatient clinics

ChatGPT in medicine: STAT answers readers' burning questions

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

hotspot

Midwives could help bridge maternal health disparities in the U.S.

Patients, doctors press FTC to beef up hospital merger scrutiny

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

'A game

Pharma budget tightening trickles down to Doximity

White House Covid adviser calls on docs to combat misinformation

focus

Wikipedia

hotspot

focus